Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Research Article

Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening

Author(s): Wei Duan, Yu Chen, Jinlu Shan* and Qian Li*

Volume 19, Issue 5, 2024

Published on: 18 October, 2023

Page: [635 - 651] Pages: 17

DOI: 10.2174/0115748928259095231010055507

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Osteosarcoma (OS) is a common primary malignant bone tumor that mainly occurs in children and adolescents. The use of IL-8 inhibitor compounds has been reported in patents, which can be used to treat and/or prevent osteosarcoma, but the pathogenesis of osteosarcoma remains to be investigated. At present, osteoblasts and osteoclasts play an important role in the occurrence and development of OS. However, the relationship between osteoblasts and osteoclasts in the specific participation mechanism and inflammatory response of OS patients has not been further studied.

Methods: The transcriptome, clinical data, and other data related to OS were downloaded from the GEO database to analyze them with 200 known inflammatory response genes. We set the screening conditions as p < 0.05 and | log2FC| > 0.50, screened the differentially expressed genes (DEGs) related to OS, tested the correlation coefficient between the OS INF gene and clinical risk, and analyzed the survival prognosis. We further enriched and analyzed the DEGs and inflammatory response genes of OS with GO/KEGG to explore the potential biological function and signal pathway mechanism of OS inflammatory response genes. Moreover, the virtual screening of drug sensitivity of OS based on the FDA drug library was also carried out to explore potential therapeutic drugs targeted to regulate OS osteogenesis and osteoclast inflammation, and finally, the molecular dynamics simulation verification of OS core protein and potential drugs was carried out to explore the binding stability and mechanism between potential drugs and core protein.

Results: Through differential analysis of GSE39058, GSE36001, GSE87624, and three other data sets closely related to OS osteoblasts and osteoclasts, we found that there was one upregulated gene (CADM1) and one down-regulated gene (PHF15) related to OS. In addition, GSEA enrichment analysis of the DEGs of OS showed that it was mainly involved in the progress of OS through biological functions, such as oxidative photosynthesis, acute junction, and epithelial-mesenchymal transition. The enrichment analysis of OS DEGs revealed that they mainly affect the occurrence and progress of OS by participating in the regulation of the actin skeleton, PI3K Akt signal pathway, complement and coagulation cascade. According to the expression of CSF3R in OS patients, a risk coefficient model and a diagnostic model were established. It was found that the more significant the difference in the CSF3R gene in OS patients, the greater the risk coefficient of disease (p < 0.05). The AUC under the curve of the CSF3R gene was greater than 0.65, which had a good diagnostic significance for OS. The above results showed that the prognosis risk gene CSF3R related to OS inflammation was closely related to the survival status of OS patients. Finally, through the virtual screening of the ZINC drug library and molecular dynamics simulation, it was found that the docking model formed by the core protein CSF3R and the compounds, Leucovorin and Methotrexate, were the most stable, which revealed that the compounds Leucovorin and Methotrexate might play a role in the treatment of OS by combining with the inflammatory response related factor CSF3R of OS.

Conclusion: CSF3R participates in the occurrence and development of OS bone destruction by regulating the inflammatory response of osteoblasts and osteoclasts and can affect the survival prognosis of OS patients.

Keywords: Osteosarcoma, inflammatory reaction, CSF3R, survival analysis, drug virtual screening, molecular dynamics simulation.

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[2]
Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021; 500: 1-10.
[http://dx.doi.org/10.1016/j.canlet.2020.12.024] [PMID: 33359211]
[3]
Franceschini N, Lam SW, Cleton-Jansen AM, Bovée JVMG. What’s new in bone forming tumours of the skeleton? Virchows Arch 2020; 476(1): 147-57.
[http://dx.doi.org/10.1007/s00428-019-02683-w] [PMID: 31741049]
[4]
Rathore R, Van Tine BA. Pathogenesis and current treatment of osteosarcoma: Perspectives for future therapies. J Clin Med 2021; 10(6): 1182.
[http://dx.doi.org/10.3390/jcm10061182] [PMID: 33809018]
[5]
Alfranca A, Martinez-Cruzado L, Tornin J, et al. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 2015; 72(16): 3097-113.
[http://dx.doi.org/10.1007/s00018-015-1918-y] [PMID: 25935149]
[6]
Roberts RD. IL-8 inhibitors for use in the treatment of some sarcomas. U.S. Patent 20210361627, 2021.
[7]
Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357(9255): 539-45.
[http://dx.doi.org/10.1016/S0140-6736(00)04046-0] [PMID: 11229684]
[8]
Jettoo P, Tan GJS, Gerrand CH, Rankin KS. Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients. J Orthop Surg 2019; 27(2)
[http://dx.doi.org/10.1177/2309499019838293] [PMID: 30909848]
[9]
Li X, Tian F, Wang F, Li Y. Serum C-reactive protein and overall survival of patients with osteosarcoma. Tumour Biol 2015; 36(7): 5663-6.
[http://dx.doi.org/10.1007/s13277-015-3240-6] [PMID: 25986475]
[10]
Kelleher FC, O’Sullivan H. Monocytes, macrophages, and osteoclasts in osteosarcoma. J Adolesc Young Adult Oncol 2017; 6(3): 396-405.
[http://dx.doi.org/10.1089/jayao.2016.0078] [PMID: 28263668]
[11]
Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103(2): 197-206.
[http://dx.doi.org/10.1172/JCI3523] [PMID: 9916131]
[12]
Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta Rev Cancer 2012; 1826(2): 434-42.
[http://dx.doi.org/10.1016/j.bbcan.2012.07.003] [PMID: 22846337]
[13]
Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011; 117(8): 1736-44.
[http://dx.doi.org/10.1002/cncr.25744] [PMID: 21472721]
[14]
Kelly AD, Haibe-Kains B, Janeway KA, et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med 2013; 5(1): 2.
[http://dx.doi.org/10.1186/gm406] [PMID: 23339462]
[15]
Scott MC, Temiz NA, Sarver AE, et al. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res 2018; 78(2): 326-37.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-0576] [PMID: 29066513]
[16]
Sipos F, Firneisz G, Műzes G. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World J Gastroenterol 2016; 22(35): 7938-50. b
[http://dx.doi.org/10.3748/wjg.v22.i35.7938] [PMID: 27672289]
[17]
Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res 2015; 3(1): 1-11.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0209] [PMID: 25568067]
[18]
Jiang Y, Wang X, Cheng Y, et al. Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review. Oncotarget 2017; 8(57): 97571-83.
[http://dx.doi.org/10.18632/oncotarget.18813] [PMID: 29228633]
[19]
Xiao X, Wang W, Li Y, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res 2018; 37(1): 201.
[http://dx.doi.org/10.1186/s13046-018-0880-6] [PMID: 30153855]
[20]
Chen G, Wang Q, Yang Q, et al. Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma. PLoS One 2018; 13(8): e0202896.
[http://dx.doi.org/10.1371/journal.pone.0202896] [PMID: 30153287]
[21]
Mizushima E, Tsukahara T, Emori M, et al. Osteosarcoma‐initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. Cancer Sci 2020; 111(1): 36-46.
[http://dx.doi.org/10.1111/cas.14229] [PMID: 31705593]
[22]
Hu X, Zhou X, Zhang J, Li L. Sphingolipid metabolism is associated with osteosarcoma metastasis and prognosis: Evidence from interaction analysis. Front Endocrinol 2022; 13: 983606.
[http://dx.doi.org/10.3389/fendo.2022.983606] [PMID: 36105405]
[23]
Yu X, Yustein JT, Xu J. Research models and mesenchymal/epithelial plasticity of osteosarcoma. Cell Biosci 2021; 11(1): 94.
[http://dx.doi.org/10.1186/s13578-021-00600-w] [PMID: 34022967]
[24]
Ni S, Li J, Qiu S, Xie Y, Gong K, Duan Y. KIF21B expression in osteosarcoma and its regulatory effect on osteosarcoma cell proliferation and apoptosis through the PI3K/AKT pathway. Front Oncol 2021; 10: 606765.
[http://dx.doi.org/10.3389/fonc.2020.606765] [PMID: 33585227]
[25]
Li H, Shen X, Ma M, et al. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway. J Exp Clin Cancer Res 2021; 40(1): 340.
[http://dx.doi.org/10.1186/s13046-021-02146-8] [PMID: 34706747]
[26]
Zhang Y, Cheng H, Li W, Wu H, Yang Y. Highly‐expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β‐catenin and mTOR/HIF1α/VEGF signaling. Int J Cancer 2019; 145(4): 1068-82.
[http://dx.doi.org/10.1002/ijc.32207] [PMID: 30761524]
[27]
Fujiyoshi S, Honda S, Minato M, et al. Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma. Hepatol Res 2020; 50(5): 598-606.
[http://dx.doi.org/10.1111/hepr.13479] [PMID: 31894653]
[28]
Su L, Gao S, Tan Y, et al. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations. Ann Hematol 2019; 98(7): 1641-6.
[http://dx.doi.org/10.1007/s00277-019-03699-7] [PMID: 31041512]
[29]
Yin CD, Hou YL, Liu XR, et al. Development of an immune-related prognostic index associated with osteosarcoma. Bioengineered 2021; 12(1): 172-82.
[http://dx.doi.org/10.1080/21655979.2020.1864096] [PMID: 33371790]
[30]
Zhang W, Zhang Q, Zheng TT, Zhen JC, Niu XH. Delayed high-dose methotrexate excretion and influencing factors in osteosarcoma patients. Chin Med J 2016; 129(21): 2530-4.
[http://dx.doi.org/10.4103/0366-6999.192781] [PMID: 27779157]
[31]
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11(6): 694-703.
[http://dx.doi.org/10.1634/theoncologist.11-6-694] [PMID: 16794248]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy